Clinical Trials Browser

Phase 2 × Leukemia, Biphenotypic, Acute × blinatumomab × Clear all

NCT06317662 2026-03-18

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT07222579 2026-01-21

Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute

NCT04827745 2025-07-03

Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL

Phase 2 Completed

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Neoplasm, Residual

NCT04044560 2022-02-21

OZM-097

Phase 2 Terminated

LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma